ROIV News and Press, Roivant Sciences Ltd. From 11/10/23

BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately. Dr. Sukhatme will fill a newly created Class III seat on the Board of Directors, increas...

BASEL, LONDON, and NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 13, 2023, to report its financial results for the second quarter ended September 30, 2023, and provide a b...

2023-10-28 07:33:42 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . For further details see: Wall Street Breakfast: What Moved Markets

2023-10-24 09:25:49 ET Summary Roche Holding AG acquires Telavant Holdings for $7.1B upfront and $150M milestone payment, potentially very interesting deal. Roivant Sciences owns a 75% equity interest in Telavant Holdings. Curiously, Roivant Sciences stock sold off on the news...

2023-10-23 07:30:26 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Spotify . For further details see: Wall Street Breakfast: Opening The Books

2023-10-23 06:42:07 ET Summary Roivant Sciences announces $7.1B deal with Roche to acquire Telavant and its new bowel disease therapy. Stonepeak to acquire Textainer Group for $2.1B. Japan's competition watchdog to investigate Google over antimonopoly practices related to its ...

2023-10-23 05:32:56 ET Stock futures fell slightly in premarket trading on Monday as U.S. Treasury yields remained near multiyear highs amid investor concerns about rising interest rates ahead of big tech earnings reports. For further details see: Biggest stock movers today: Crypto-...

2023-10-23 03:10:38 ET More on Roche, Roivant Sciences Skin In The Game: Behind Roivant's Significant Rise Be Patient, Roche Is A Clear Buy At This Price Roche: Positive Readouts From Pipeline Roche: 2023 Should Mark The Bottom Roche slips after in-li...

Roche will gain the rights to develop, manufacture and commercialize RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseases RVT-3101 is a Phase 3-ready antibody with first-in-class and best-in-disease potential, a novel mode of act...

2023-10-13 08:10:01 ET More on Roivant Sciences Skin In The Game: Behind Roivant's Significant Rise Immunovant to raise $450M from public offering and private placement Immunovant stock rallies for second day, fueled by public offering, drug data For further ...